Prestige Consumer Healthcare Inc. announced record financial results for its fourth quarter and full fiscal year ended March 31, 2025. Fourth-quarter revenues reached $296.5 million, a 7.0% increase from the prior year, with adjusted diluted earnings per share of $1.32, up from $1.02.
For the full fiscal year 2025, the company reported record revenues of $1,137.8 million, an increase of 1.1% over the prior fiscal year, and adjusted diluted earnings per share of $4.52, up from $4.21. This performance was supported by strong growth in the Gastrointestinal category and the International OTC segment.
Prestige Consumer Healthcare generated $243.3 million in free cash flow for fiscal 2025, an increase of 1.6% year-over-year, and repurchased approximately 0.7 million shares for $51.5 million. The company's net debt stood at approximately $0.9 billion, resulting in a covenant-defined leverage ratio of 2.4x.
Looking ahead to fiscal 2026, the company provided an initial outlook anticipating organic revenue growth of approximately 1% to 2% and adjusted EPS in the range of $4.70 to $4.82. Management noted an expected $15 million headwind related to inflationary impacts of enacted tariffs, which they plan to mitigate through strategic actions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.